Prespecified interim analysis of 639 adults with previously treated CLL/SLL: adding pirtobrutinib to fixed-duration venetoclax-rituximab improved progression-free survival vs venetoclax-rituximab (HR 0·547; 24-month PFS 87% vs 72%). Grade ≥3 adverse events 79% vs 73%.
RCTn = 639
Davids et al. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial